\
&
Contact us
\
&
Contact us
This was 8 months ago
LocationOnline
ProgrammesThe Language Technology Landscape Conference disseminates the findings from the Market Study conducted by Nimdzi Insights.
Nimdzi Insights and its partners are conducting a comprehensive Market Study on Language Technologies for the European Commission to assess the development, quality, and global impact of language technologies globally and in Europe. The Language Technology Landscape Conference will present the results of a two-year study, highlighting trends in the language technology market with a focus on foundational, text-based, and speech-based language technologies. This half-day online event will be hosted on WebEx, with keynote speakers from the European Commission and Nimdzi Insights, as well as guest appearances from the buyer and technology provider sides.
For more information and to register for the event, please visit the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
